Literature DB >> 28840581

Dishevelled proteins and CYLD reciprocally regulate each other in CML cell lines.

Ceyda Çalışkan1,2, Melek Pehlivan1,3, Zeynep Yüce1, Ogun Sercan4.   

Abstract

Dishevelled (Dvl) proteins are activated by Wnt pathway stimulation and have crucial roles in the regulation of β-catenin destruction complex. CYLD is a tumor suppressor and a deubiquitination enzyme. CYLD negatively regulates the Wnt/β-catenin signaling pathway by deubiquitinating Dvl proteins. Loss of function and mutations of CYLD were linked to different types of solid tumors. Loss of function in CYLD is associated with Dvl hyper ubiquitination, resulting in the transmission of Wnt signaling to downstream effectors. β-catenin upregulation is observed during disease progression in chronic myeloid leukemia (CML). Deregulated Dvl signaling may be a reason for β-catenin activation in CML; and CYLD may contribute to Dvl deregulation. First, we evaluated mRNA expression in three CML cell lines and mRNA expression of the CYLD gene was found to be present in all (K562, MEG01, KU812). Unlike solid tumors sequencing revealed no mutations in the coding sequences of the CYLD gene. DVL genes were silenced by using a pool of siRNA oligonucleotides and gene expression differences in CYLD was determined by RT-PCR and western blot. CYLD protein expression decreased after Dvl silencing. An opposite approach of overexpressing Dvl proteins resulted in upregulated CYLD expression. While previous reports have described CYLD as a regulator of DVL proteins; our data suggests the presence of a more complicated reciprocal regulatory mechanism in CML cell lines.

Entities:  

Keywords:  CML; CYLD; Dishevelled; Wnt/β-catenin signaling pathway

Mesh:

Substances:

Year:  2017        PMID: 28840581     DOI: 10.1007/s11033-017-4122-3

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  29 in total

1.  Identification of the familial cylindromatosis tumour-suppressor gene.

Authors:  G R Bignell; W Warren; S Seal; M Takahashi; E Rapley; R Barfoot; H Green; C Brown; P J Biggs; S R Lakhani; C Jones; J Hansen; E Blair; B Hofmann; R Siebert; G Turner; D G Evans; C Schrander-Stumpel; F A Beemer; A van Den Ouweland; D Halley; B Delpech; M G Cleveland; I Leigh; J Leisti; S Rasmussen
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

2.  Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.

Authors:  Matthew W Jenner; Paola E Leone; Brian A Walker; Fiona M Ross; David C Johnson; David Gonzalez; Laura Chiecchio; Elisabet Dachs Cabanas; Gian Paolo Dagrada; Mathew Nightingale; Rebecca K M Protheroe; David Stockley; Monica Else; Nicholas J Dickens; Nicholas C P Cross; Faith E Davies; Gareth J Morgan
Journal:  Blood       Date:  2007-07-03       Impact factor: 22.113

Review 3.  CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.

Authors:  S-C Sun
Journal:  Cell Death Differ       Date:  2010-01       Impact factor: 15.828

Review 4.  Dishevelled: The hub of Wnt signaling.

Authors:  Chan Gao; Ye-Guang Chen
Journal:  Cell Signal       Date:  2009-12-13       Impact factor: 4.315

5.  Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.

Authors:  S Zhong; C R Fields; N Su; Y-X Pan; K D Robertson
Journal:  Oncogene       Date:  2006-10-09       Impact factor: 9.867

6.  Reduced expression of CYLD in human colon and hepatocellular carcinomas.

Authors:  Claus Hellerbrand; Elisabeth Bumes; Frauke Bataille; Wolfgang Dietmaier; Ramin Massoumi; Anja K Bosserhoff
Journal:  Carcinogenesis       Date:  2006-06-13       Impact factor: 4.944

7.  The expression and significance of dishevelled in human glioma.

Authors:  Jian Li; Geng Guo; Jin Li; Jiehe Hao; Jianjun Zhang; Yongping Guo; Hui Yu
Journal:  J Surg Res       Date:  2014-06-24       Impact factor: 2.192

8.  The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.

Authors:  Andrew Kovalenko; Christine Chable-Bessia; Giuseppina Cantarella; Alain Israël; David Wallach; Gilles Courtois
Journal:  Nature       Date:  2003-08-14       Impact factor: 49.962

Review 9.  Runnin' with the Dvl: proteins that associate with Dsh/Dvl and their significance to Wnt signal transduction.

Authors:  Keith A Wharton
Journal:  Dev Biol       Date:  2003-01-01       Impact factor: 3.582

Review 10.  Targeting the canonical Wnt/β-catenin pathway in hematological malignancies.

Authors:  Eishi Ashihara; Tetsuya Takada; Taira Maekawa
Journal:  Cancer Sci       Date:  2015-04-01       Impact factor: 6.716

View more
  1 in total

Review 1.  Deubiquitinating Enzymes Orchestrate the Cancer Stem Cell-Immunosuppressive Niche Dialogue: New Perspectives and Therapeutic Potential.

Authors:  Jun-Nan Guo; Bai-Rong Xia; Shen-Hui Deng; Chang Yang; Ya-Nan Pi; Bin-Bin Cui; Wei-Lin Jin
Journal:  Front Cell Dev Biol       Date:  2021-06-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.